The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 4, 2004, Pages 437-444

  Fraser, William D ^a   Ahmad, Aftab M ^a   Vora, Jiten P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bone markers; Bone metabolism; Circadian rhythm; Growth hormone; Osteoporosis; Parathyroid hormone

Indexed keywords

CALCIUM; GROWTH HORMONE DERIVATIVE; LOOP DIURETIC AGENT; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; PHOSPHATE;

AGING; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; CALCIUM METABOLISM; CALCIUM TRANSPORT; CIRCADIAN RHYTHM; DRUG EFFECT; FRAGILITY FRACTURE; GROWTH HORMONE DEFICIENCY; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; OSTEOLYSIS; PARATHYROID FUNCTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

ADULT; BONE AND BONES; CIRCADIAN RHYTHM; FEMALE; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 3142583430     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000133985.29880.34     Document Type: Review

References (46)

1. Jubiz W, Canterbury JM, Reiss E, Tyler FH. Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. J Clin Invest 1972; 51:2040-2046.
2. Markowitz ME, Arnaud S, Rosen JF, et al. Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations. J Clin Endocrinol Metab 1988; 67:1068-1073.
3. Radjaipour M, Kindtner E, Rosler H, Eggstein M. Circadian rhythm of parathyrin and calcitonin concentrations in the serum. J Clin Chem Clin Biochem 1986; 24:175-178.
4. Sinha TK, Miller S, Feming J, et al. Demonstration of a diurnal variation in serum parathyroid hormone in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 1975; 41:1009-1013.
5. Logue FC, Fraser WD, O'Reilly DStJ, Beastall GH. The circadian rhythm of intact parathyroid hormone (1-84) and nephrogenous cyclic adenosine monophosphate in normal men. J Endocrinol 1989; 121:R1-R3.
6. Logue FC, Fraser WD, Gallacher SJ, et al. The loss of circadian rhythm for intact parathyroid hormone and nephrogenous cyclic AMP in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 1990; 32:475-483.
7. Lobaugh B, Neelon FA, Oyama H, et al. Circadian rhythms for calcium, inorganic phosphorus, and parathyroid hormone in primary hyperparathyroidism: functional and practical considerations. Surgery 1989; 106:1009-1016.
8. Calvo MS, Eastell R, Offord KP, et al. Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis. J Clin Endocrinol Metab 1991; 72:69-76.
9. Fraser WD, Logue FC, Christie JP, et al. Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis. Osteoporos Int 1998; 8:121-126.
10. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 1999; 140:332-337.
11. Fraser WD, Logue FC, Christie JP, et al. Alteration of the circadian rhythm of intact parathyroid hormone following a 96-hour fast. Clin Endocrinol (Oxf) 1994; 40:523-528.
12. Li F, Muhlbauer RC. Food fractionation is a powerful tool to increase bone mass in growing rats and to decrease bone loss in aged rats: modulation of the effect by dietary phosphate. J Bone Miner Res 1999; 14:1457-1465.
13. Muhlbauer RC, Fleisch H. The diurnal rhythm of bone resorption in the rat: effect of feeding habits and pharmacological inhibitors. J Clin Invest 1995; 95:1933-1940.
14. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
15. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9-17. The anabolic effect of intermittent PTH-(1-34) treatment in men was demonstrated with increases in BMD and decreased vertebral fractures.
16. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:18-23. The previously reported effects of PTH-(1-34) in postmenopausal osteoporosis were shown to be independent of age, BMD and vertebral fractures, answering several questions regarding the initial report [14].
17. Logue FC, Fraser WD, O'Reilly DStJ, et al. The circadian rhythm of intact parathyroid hormone-(1-84): temporal correlation with prolactin secretion in normal men. J Clin Endocrinol Metab 1990; 71:1556-1560.
18. Logue FC, Fraser WD, O'Reilly DStJ, et al. Sleep shift dissociates the nocturnal peaks of parathyroid hormone (1-84), nephrogenous cyclic adenosine monophosphate, and prolactin in normal men. J Clin Endocrinol Metab 1992; 75:25-29.
19. Chapotot F, Gronfier C, Spiegel K, et al. Relationships between intact parathyroid hormone 24-hour profiles, sleep-wake cycle, and sleep electroencephalographic activity in man. J Clin Endocrinol Metab 1996; 81:3759-3765.
20. el Hajj FG, Klerman EB, Brown EN, et al. The parathyroid hormone circadian rhythm is truly endogenous: a general clinical research center study. J Clin Endocrinol Metab 1997; 82:281-286.
21. Calvo MS, Kumar R, Heath H III. Elevated secretion and action of serum parathyroid hormone in young adults consuming high phosphorus, low calcium diets assembled from common foods. J Clin Endocrinol Metab 1988; 66:823-829.
22. Calvo MS, Kumar R, Heath H. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets. J Clin Endocrinol Metab 1990; 70:1334-1340.
23. Bell NH, Williamson BT, Hollis BW, Riggs BL. Effects of race on diurnal patterns of renal conservation of calcium and bone resorption in premenopausal women. Osteoporos Int 2001; 12:43-48.
24. Sairanen S, Tahtela R, Laitinen K, et al. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. Calcif Tissue Int 1994; 55:349-352.
25. Fujita T, Ohgitani S, Fujii Y. Overnight suppression of parathyroid hormone and bone resorption markers by active absorbable algae calcium: a double-blind crossover study. Calcif Tissue Int 1997; 60:506-512.
26. Blumsohn A, Herrington K, Hannon RA, et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 1994; 79:730-735.
27. Ledger GA, Burritt MF, Kao PC, et al. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 1995; 80:3304-3310.
28. Kennel KA, Riggs BL, Achenbach SJ, et al. Role of parathyroid hormone in mediating age-related changes in bone resorption in men. Osteoporos Int 2003; 14:631-636. A lack of difference in effect of infused calcium on PTH rhythms in young and elderly men was reported, which contrasted with the effects seen in women.
29. Zikan V, Haas T, Stepan JJ. Acute effects in healthy women of oral calcium on the calcium-parathyroid axis and bone resorption as assessed by serum beta-CrossLaps. Calcif Tissue Int 2001; 68:352-357.
30. Goodman WG, Misra S, Veldhuis JD, et al. Altered diurnal regulation of blood ionized calcium and serum parathyroid hormone concentrations during parenteral nutrition. Am J Clin Nutr 2000; 71:560-568.
31. Schoofs MW, van der KM, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139:476-482. In a prospective study, thiazide diuretics were shown to significantly reduce hip fracture, but the effect was lost 4 months after stopping treatment.
32. Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion: a randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women. Eur J Clin Invest 2001; 31:764-772.
33. Rejnmark L, Lauridsen AL, Vestergaard P, et al. Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol 2002; 146:635-642.
34. White HD, Ahmad AM, Vora JP. Effects of adult growth hormone deficiency and growth hormone replacement on circadian rhythmicity. Minerva Endocrinol 2003; 28:13-25. A comprehensive review of the effects of growth hormone on bone metabolism, with a particular emphasis on PTH circadian rhythms and end organ response.
35. Ahmad AM, Hopkins MT, Fraser WD, et al. Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 2003; 32:170-179. Demonstration of the significant differences in circadian rhythms of bone-related measurements and Ca, bone and PTH metabolism in growth hormone deficient individuals compared with normal adults.
36. Ahmad AM, Thomas J, Clewes A, et al. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab 2003; 88:2860-2868. A significant alteration in end organ response to PTH was observed following growth hormone replacement in AGHD patients.
37. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res 2003; 18:393-405. The importance of following growth hormone therapy long term was emphasized by the significant effects seen on bone after 2-5 years of growth hormone treatment.
38. Malluche HH, Sherman D, Meyer W, et al. Effects of long-term infusion of physiologic doses of 1-34 PTH on bone. Am J Physiol Renal Physiol 1982; 242:F197-F201.
39. Podbesek R, Edouard C, Meunier PJ, et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 1983; 112:1000-1006.
40. Fox J, Miller MA, Stroup GB, et al. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone 1997; 21:163-169.
41. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:5644-5649. Medical treatment for primary hyperparathyroidism becomes a reality with demonstration of normalization of serum Ca in patients treated with cinacalcet, which acts by having an agonist effect via the Ca-sensing receptor.
42. Quarles LD, Sherrard DJ, Adler S, et. al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14:575-583. An oral calcimimetic is shown to significantly decrease PTH secretion in patients with renal failure, offering the possibility of manipulation of PTH secretion as treatment for metabolic bone disease.
43. 4.
44. Miller MA, Fox J. Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slows the rate of bone loss but does not increase bone mass in ovariectomized rats. Bone 2000; 27:511-519.
45. Gowen M, Stroup GB, Dodds RA, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000; 105:1595-1604.
46. Nemeth EF, Delmar EG, Heaton WL, et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther 2001; 299:323-331.